Management of Adverse Events – IO/IO and IO/TKI
The panelists compare the adverse event profiles of immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) regimens, and address the economic implications of managing long-term side effects.
EP: 1.Current treatment options for ccRCC based on patient and disease factors
EP: 2.CheckMate-214: Long-term follow-up data
EP: 3.Review of CheckMate-214: Long-term follow-up in favorable risk subgroup
EP: 4.Review of CLEAR and CheckMate-9ER: Four-Year and 55 Month Follow-Up Data
EP: 5.Review of KEYNOTE-426: Five-year Follow-up Data
EP: 6.Discontinuation or Continuation of IO Therapy – IO/IO vs. IO/TKI Regimens
EP: 7.Treatment-free survival in IO/TKI
EP: 8.Biomarkers: Impact on Treatment Choices and Future Expectations
EP: 9.Management of Adverse Events – IO/IO and IO/TKI
EP: 10.New formulations for current therapies – SC vs. IV
EP: 11.Novel Agents/Combinations for aRCC
- Please discuss adverse events associated with IO/IO vs. IO/TKI regimens.
- What impact do the AE profiles of these combinations have on your selection of systemic therapy for treatment-naïve patients with aRCC?
- What is the financial impact of managing long-term AEs?
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Belzutifan Demonstrates Superior PFS, ORR vs Everolimus in Advanced RCC
August 23rd 2024LITESPARK-005 showed that belzutifan improved progression-free survival and objective response vs everolimus in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint and antiangiogenic therapies.
Read More
Ornstein Discusses TKI Dose Interruption and Discontinuation in Combination RCC Therapy
August 19th 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, discussed dose modification approaches for patients receiving combination immunotherapy/tyrosine kinase inhibitor therapy for advanced renal cell carcinoma.
Read More
